Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31818Editorial articleПередовая статьяResearch ArticleApproaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentanПодходы к терапии легочной артериальной гипертензии: роль антагониста рецепторов эндотелина бозентанаAvdeevS NАвдеевС Н«НИИ пульмонологии» ФМБА России15092015879VOL 87, NO9 ()ТОМ 87, №9 (2015)647110042020Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31818

Pulmonary hypertension (PH) is a specific clinical group of severe and rare diseases with similar morphological, hemodynamic, and therapeutic characteristics. Despite the fact that there have been international conciliative documents and advances in drug therapy for PH, the long-term prognosis of the disease in these patients remains rather poor. Clinical trials have demonstrated that bosentan therapy in patients with PH improves pulmonary hemodynamics and exercise endurance and delays the development of the disease. According to the data of long-term studies, as compared to the historical control, bosentan used as a first-line drug can improve survival in PH patients.

Легочная артериальная гипертензия (ЛАГ) — специфическая клиническая группа тяжелых и редких заболеваний со сходными морфологическими, гемодинамическими и терапевтическими характеристиками. Несмотря на появление международных согласительных документов и успехи в медикаментозной терапии ЛАГ, долгосрочный прогноз исхода заболевания у таких пациентов остается достаточно плохим. Клинические исследования продемонстрировали, что терапия бозентаном пациентов с ЛАГ приводит к улучшению легочной гемодинамики, переносимости физических нагрузок и замедлению развития заболевания. Согласно данным длительных исследований, бозентан, назначенный как препарат терапии первой линии, позволяет улучшить выживаемость пациентов ЛАГ, по сравнению с историческим контролем.

pulmonary hypertensionendothelin receptor antagonistsbosentanлегочная артериальная гипертензияантагонисты рецепторов эндотелинабозентанHoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-D50. doi:10.1016/j.jacc.2013.10.032.Primary Pulmonary Hypertension: Report of a WHO Meeting. Eds. Hatano S, Strasser T, Geneva: World Health Organization. 1975. doi:10.1016/s0002-8703(76)80167-6.D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al (Division of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD 20892.) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-349. doi:10.7326/0003-4819-115-5-343.Galiè N, Hoeper M, Humbert M, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537. doi:10.1093/eurheartj/ehp297.Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor KH, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Subirana Domenech MT, Vonk-Noordegraaf A, Zamorano JL. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263. doi:10.1183/09031936.00139009.Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007;153:1037-1047. doi:10.1016/j.ahj.2007.02.037.Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med. 2007;28:233-241. doi:10.1016/j.ccm.2006.12.001.Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Kumar RK, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34-D41. doi:10.1016/j.jacc.2013.10.029.Pietra GG, Edwards WD, Kay JM, Pietra GG, Edwards WD, Kay JM et al. (Division of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland.) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198–206 et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-1206. doi:10.1161/01.cir.80.5.1198.Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43:S25-S32. doi:10.1016/j.jacc.2004.02.033.Humbert M1, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:S13-S24. doi:10.1016/j.jacc.2004.02.029.Humbert M, Sitbon O, Chaouat A, aud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030. doi:10.1164/rccm.200510-1668oc.Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-109. doi:10.1183/09031936.00092306.Thenappan T, Ryan JJ, Archer SL. Evolving Epidemiology of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2012;186:706-709. doi:10.1164/rccm.201207-1266ed.McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294. doi:10.1161/circulationaha.109.192230.Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-359. doi:10.1183/09031936.04.00028404.Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691-694. doi:10.1183/09031936.06.00057906.Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521-530. doi:10.7326/0003-4819-149-8-200810210-00004.Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31:407-415. doi:10.1183/09031936.00078207.Galiè N, Manes A, Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res. 2004;61:227-237. doi:10.1016/j.cardiores.2003.11.026.Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562-1569. doi:10.1378/chest.120.5.1562.Bauer M, Wilkens HC, Langer F, Schneider SO, Lausberg H, Schäfers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034-1036. doi:10.1161/hc0902.105719.Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med. 2007;28:117-125. doi:10.1016/j.ccm.2006.11.002.Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123. doi:10.1016/s0140-6736(01)06250-x.Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med. 2002;346:896-903. doi:10.1056/nejmoa012212.Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M. Bosentan therapy in patients 1626 with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114: 48-54. doi:10.1161/circulationaha.106.630715.Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093-2100. doi:10.1016/s0140-6736(08)60919-8.Мартынюк Т.В., Архипова О.А., Кобаль Е.А. Применение неселективного антагониста рецепторов эндотелина бозентана у больных идиопатической легочной гипертензией: первый российский опыт и взгляд в будущее. Системные гипертензии. 2011;4:3-7.Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. Effects of the dual endothelin-1 receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124: 247-254. doi:10.1378/chest.124.1.247.Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589-595. doi:10.1093/eurheartj/ehi728.Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Intern J Cardiol. 2014;172:332-339. doi:10.1016/j.ijcard.2013.12.179.Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты 1-годичного исследования. Терапевтический архив. 2013;3:38-43.McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ.Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-249. doi:10.1183/09031936.05.00028005.Roman A, Gispert P, Monfort V, Bravo C, Domingo E, Morell F. Long-term outcomes of treatment with bosentan in pulmonary hypertension. Arch Bronconeumol. 2006;42:616-620. doi:10.1016/s1579-2129(07)60002-0.Чазова И.Е., Авдеев С.Н., Царева Н.А., Волков А.В., Мартынюк Т.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив 2014;9:4-23.